StreetInsider.com News Articles

Form EFFECT YD Bio Ltd

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578481.html

Form POS AM YD Bio Ltd

Tue, 26 May 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260526/26551292.html

Form 6-K YD Bio Ltd For: Apr 30

Fri, 01 May 2026 09:47:00 -0400

si-local-file:///var/storage/secattach/20260501/26413826.html

YD Bio Limited Reports Full Year 2025 Financial Results

Thu, 30 Apr 2026 18:00:00 -0400

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025.

Management Commentary
“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our

YD Bio Limited Reports Full Year 2025 Financial Results

Thu, 30 Apr 2026 18:00:00 -0400

Form 20-F YD Bio Ltd For: Dec 31

Thu, 30 Apr 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260430/26408922.html

Form 3/A YD Bio Ltd For: Mar 18 Filed by: Lu Shao-Ta

Mon, 20 Apr 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20260420/26335741.html

Form 4 YD Bio Ltd For: Mar 31 Filed by: Chang Kochi

Thu, 02 Apr 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260402/26266460.html

Form 4 YD Bio Ltd For: Mar 31 Filed by: Lu Shao-Ta

Thu, 02 Apr 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260402/26266493.html

Form 3 YD Bio Ltd For: Mar 18 Filed by: Lu Shao-Ta

Thu, 02 Apr 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260402/26266378.html

Form 3 YD Bio Ltd For: Mar 18 Filed by: Chang Kochi

Thu, 02 Apr 2026 07:27:00 -0400

si-local-file:///var/storage/secattach/20260402/26262481.html

YD Bio launches telehealth platform for cancer detection services

Tue, 31 Mar 2026 08:05:20 -0400

YD Bio Limited (NASDAQ: YDES) and EG BioMed Co. launched the EG Telehealth Platform, enabling cancer detection services across 44 U.S. states, Washington D.C., and Guam. The platform went live on March 31, 2026, according to a company statement.

The collaboration combines YD Bio's digital health platform with EG BioMed's CLIA/CAP-certified laboratory capabilities. The platform operates through a network of licensed physicians and supports detection for multiple cancer types including pancreatic, colorectal, liver, gastrointestinal, and breast cancers.

The telehealth system uses YD Bio's DNA methylation-based cancer detection technology and provides what the companies describe as a decentralized approach to diagnostic service delivery.

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Tue, 31 Mar 2026 08:00:00 -0400

Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company’s commercialization of early cancer detection and decentralized clinical service delivery across the United States.

The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam,

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Tue, 31 Mar 2026 08:00:00 -0400

The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam,

Form 3 YD Bio Ltd For: Mar 18 Filed by: Lee Jerry Yin-Chia

Mon, 30 Mar 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260330/26240848.html

Form 3 YD Bio Ltd For: Mar 18 Filed by: Zhang Bo-Xiang

Fri, 27 Mar 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260327/26233354.html

Form 3 YD Bio Ltd For: Mar 18 Filed by: Hen Man Edmund

Thu, 26 Mar 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260326/26224179.html

Form 3 YD Bio Ltd For: Mar 18 Filed by: Shen Ethan PhD

Wed, 18 Mar 2026 10:51:00 -0400

si-local-file:///var/storage/secattach/20260318/26182099.html

YD Bio outlines integrated oncology platform strategy

Tue, 17 Mar 2026 08:01:20 -0400

YD Bio Limited (NASDAQ: YDES) detailed its strategic approach to building an integrated oncology ecosystem that combines cancer detection technology with therapeutic development. The biotechnology company's CEO Dr. Ethan Shen outlined the roadmap in an interview with PharmaBoardroom, a healthcare industry platform.

The company is developing what it describes as a comprehensive system that connects early cancer detection programs with late-stage dendritic cell immunotherapy. YD Bio aims to use diagnostic data to monitor therapeutic responses, creating what the company calls a feedback loop for clinical decision-making.

YD Bio has established regulatory infrastructure by serving as an Official U.S. Agent for FDA submissions

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

Tue, 17 Mar 2026 08:00:00 -0400

Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution.

In the interview, Dr. Shen addressed the Company’s approach to the

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

Tue, 17 Mar 2026 08:00:00 -0400

In the interview, Dr. Shen addressed the Company’s approach to the

Form 424B3 YD Bio Ltd

Fri, 27 Feb 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260227/26077209.html

Form 6-K YD Bio Ltd For: Feb 26

Thu, 26 Feb 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260226/26068778.html

YD Bio partners with YC Biotech for Taiwan-US regulatory platform

Wed, 25 Feb 2026 08:00:44 -0400

YD Bio Limited (NASDAQ: YDES) announced that its subsidiary YD Bio USA entered into a strategic alliance agreement with YC Biotech Co., Ltd. on February 24, 2026. The partnership establishes YD Bio USA as the exclusive U.S. agent for FDA regulatory applications for YC Biotech's contract research organization clients in Asia.

Under the agreement, YD Bio USA will serve as YC Biotech's official liaison with the FDA, managing communications, representing sponsors in regulatory meetings, and providing compliance advisory services. YC Biotech will handle project acquisition, technical execution, and preparation of submission documentation including IND, NDA, and BLA filings.

The collaboration will cover

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

Wed, 25 Feb 2026 08:00:00 -0400

Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. (“YD Bio USA”) entered into a Master Strategic Alliance Agreement (the “Agreement”) with YC Biotech Co., Ltd. (“YC Biotech”) on February 24, 2026. This partnership represents a pivotal advancement in the Company’s mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration (the